John M Burke, MD from Rocky Mountain Cancer Centers discusses new Phase 3 Murano trial for CLL and Venetoclax & Rituximab superior to Bendamustine & Rituximab at the 2017 American Society of Hematology.
John M Burke, MD from Rocky Mountain Cancer Centers discusses new Phase 3 Murano trial for CLL and Venetoclax & Rituximab superior to Bendamustine & Rituximab at the 2017 American Society of Hematology.